business

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

Forbes · Jun 4, 2026, 10:30 AM · Also reported by 3 other sources

Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks to raise $400 million more VC funding at a $3.4 billion valuation, Forbes has learned.

Read full story on Forbes → More top stories

Also covered by

Investing.com Alnylam, Inceptive form AI drug discovery collaboration Bloomberg Tech Nvidia-Backed Robotics Startup Generalist AI Valued at $2 Billion Healthline Lilly's New Drug Yields Dramatic Weight Loss, Rivaling Bariatric Surgery, GLP-1s

Aggregated and edited by the Scoop newsroom. We surface news from Forbes alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

Also covered by

More in business